Katerina Chatzidionysiou

TL;DR: Addition of GCs to csDMARD therapy may be beneficial but the benefits should be balanced against the risk of toxicity, and tofacitinib and baricitinib are efficacious in patients with RA, including those with refractory disease.

TL;DR: Effectiveness was best when RTX was used as the first biological agent or after failure of no more than one anti-tumour necrosis factor agent and seropositive patients achieved significantly greater reductions in DAS28 at 6 months than seronegative patients.

TL;DR: For many patients who fail initial methotrexate treatment, add-on treatment with disease-modifying antirheumatic drugs is an appropriate treatment option, and improved clinical outcomes after 12 months and better radiographical results after 24 months should be weighed against the absence of a convincing clinical difference at 24 months and substantially higher costs.

TL;DR: This systematic literature review consistently confirmed the previously reported efficacy of bDMARDs in RA and provided additional information on b DMARD switching and dose reduction.

TL;DR: Although PGA is associated with objective measures of disease activity, it is also associated with other aspects of health, such as psychological distress or comorbidities, which leads to situations of discordance between objective RA assessments and PGA.